Increased levels of calbindin-D in serum and urine from patients treated by extracorporeal shock wave lithotripsy.
Calbindin-D 28 kDa. is a vitamin D-dependent calcium binding protein that is found mainly in the distal renal tubules and central nervous tissue in humans. Calbindin-D was measured in the serum and urine before, and immediately, 2 hours or 24 hours after extracorporeal shock wave lithotripsy (ESWL*) in 83 consecutive patients. ESWL was performed with the Siemens Lithostar device in 61 patients and with the Dornier MPL9000 lithotriptor in 22. The serum 28 kDa. calbindin-D level was undetectable (less than 20 pg./ml.) in many samples, whereas urinary 28 kDa. calbindin-D could be detected in every sample. The serum 28 kDa. calbindin-D level was usually elevated after ESWL and the concentration in patients treated with the MPL9000 device was greater than in those treated with the Lithostar instrument. Urinary 28 kDa. calbindin-D levels were elevated significantly immediately and at 2 hours after ESWL, and they decreased to the baseline level within 24 hours after ESWL in the Lithostar group but remained consistently significantly elevated after ESWL in the MPL9000 group. This fact may be because the MPL9000 lithotriptor produces a stronger shock wave than does the Lithostar device during ESWL. These results suggest that 28 kDa. calbindin-D is released from damaged distal renal tubule cells into the serum and urine during ESWL and that 28 kDa. calbindin-D is a specific marker for renal damage by ESWL. To our knowledge this is the first clinical study using a sensitive enzyme immunoassay for human 28 kDa. calbindin-D to estimate renal damage during ESWL.
Hasegawa
S
S
Department of Urology, Nagoya University School of Medicine, Japan.
Kato
K
K
Takashi
M
M
Zhu
Y
Y
Obata
K
K
Kinukawa
T
T
Miyake
K
K
D000328:Adult; D064026:Calbindins; D005260:Female; D006801:Humans; D006869:Hydronephrosis / Q000378:metabolism; D007124:Immunoenzyme Techniques; D007669:Kidney Calculi / Q000628:therapy*; D007686:Kidney Tubules, Distal / Q000293:injuries*; D008096:Lithotripsy / Q000009:adverse effects* / Q000295:instrumentation; D008297:Male; D008875:Middle Aged; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*; D014514:Ureteral Calculi / Q000628:therapy*
D064026:Calbindins; D064030:S100 Calcium Binding Protein G